IQVIA Holdings Inc. (IQV)
NYSE · Durham, North Carolina, USA · Founded 1982 · CEO Ari Bousbib
Valuation summary
$218.35 fair value versus $250.55 in the market, a difference of -12.8%. Rated Reduce.
| Fair value per share | $218.35 |
| Current share price | $250.55 |
| Upside / downside | -12.8% |
| Bear case | $111.90 |
| Bull case | $372.34 |
| Discount rate (WACC) | 9.4% |
| Terminal growth | 2.60% |
| Market capitalisation | $41B |
| EV / Sales | 3.2x |
About IQVIA Holdings Inc.
Formed by the 2016 merger of IMS Health and Quintiles. Ari Bousbib has been CEO since. IQVIA runs clinical trials for pharmaceutical companies as a contract research organisation, and separately sells the prescription and healthcare data the industry uses for commercial decisions. Combining trial execution with data ownership is unusual and hard to replicate.
Investment case
- Combining trial execution with proprietary healthcare data is a genuinely differentiated position.
- A large committed backlog gives multi-year revenue visibility.
- Drug development activity grows structurally regardless of which drugs succeed.
Key risks
- Biotech funding weakness reduces the volume of trials being started.
- Large pharmaceutical clients have been consolidating vendor spend and pushing on price.
- Meaningful debt load from the merger and subsequent acquisitions.
Recent developments
- 2026-10-27 · Q3 revenue up 8% to $4.43bn with record R&D Solutions bookings; full-year 2026 guidance raised source
- 2026-09-29 · IQVIA will report third-quarter 2026 results on 27 October 2026. source
- 2026-09-09 · IQVIA priced $2.0bn of 6.375% senior notes due 2034 to redeem its 5.000% 2026 notes and repay part of its revolver. source
Revenue by segment
| Research & Development Solutions | 58% |
| Technology & Analytics | 37% |
| Contract Sales | 5% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $18.6B | $2.2B |
| Year 2 | $20.2B | $2.5B |
| Year 3 | $22.0B | $2.8B |
| Year 4 | $24.0B | $3.1B |
| Year 5 | $26.1B | $3.5B |
What the street says
Viewed as the leading contract research organisation, with the debate centred on biotech funding recovery.
Comparable companies: BSX · GEHC · TEVA · MDLN · TAK · HCA · CI · MDT
Open the interactive model, price chart and sensitivity grid →